Norstella

In Vivo Podcasts

Business EN ↓ 34 episodes

The In Vivo Podcast, hosted by David Wild and Anabel Costa-Ferreira, explores the trends, innovations and strategies shaping global life sciences. Designed for biotech and pharmaceutical professionals, episodes feature journalists and industry leaders analyzing emerging technologies, R&D and market forces. Stay ahead with expert insight and intelligence. Visit https://insights.citeline.com/in-vivo for daily newsletters and life sciences commercial intelligence.

Be sure to visit the podcast's website and support the creator: insights.citeline.com

Author

Norstella

Category

Business

Podcast website

insights.citeline.com

Latest episode

Nov 20, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

Due Diligence Podcast: Why Are Reverse Mergers Increasing Despite Rising IPO Activity 20.11.2026

Biotech execs Matt Davidson and Sheila Gujrathi and attorney Mike Blankenship join Scrip’s Joseph Haas to discuss the uptick of reverse mergers in 2026 and the factors driving that trend.

Strategic Intent: Praxis CEO On Unlearning, AI And Launching Two Neuroscience Drugs At Once 17.11.2026

Praxis Precision Medicines is within weeks of FDA decisions on two potential firsts: relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies, and ulixacaltamide for essential tremor. In this episode of Strategic Intent, In Vivo senior reporter David Wild talks with Praxis CEO Marcio Souza about the company’s philosophy of “unlearning,” how AI is embedded across the organizatio...

Special Episode: Topspin and Why Product Demand, Not Coverage, Drives Formulary Power 13.11.2026

Conventional wisdom says you secure coverage first, then build demand. What if the causality runs the other way? In this special In Vivo podcast episode, senior reporter David Wild talks with Harris Kaplan (managing partner, Litmys), Sal Grouso (senior market access executive), and Roxanne Schwans (founder and CEO, OmniHealth Rx Advisors). Kaplan and Grouso recently published an article in In Vivo...

Strategic Intent: Lundbeck On Reimbursement, Risk And The Return Of Neuroscience 10.11.2026

In this episode of Strategic Intent, Maria Alfaiate, Executive Vice President for Corporate Portfolio and Product Strategy at Lundbeck, discusses neuroscience's growing resurgence in pharmaceutical investment alongside other challenges faced in central nervous system dealmaking decisions.

Proof of Concept: The Money Is Back In RNA, But What Stands Between Headlines And Routine Medicine? 06.11.2026

"The money is back in RNA. In recent weeks, Merck KGaA agreed to pay about $1.1 billion for Silence Therapeutics, Novartis signed a deal worth up to $7.8 billion with Abogen Biosciences, and Roche paid more than $1 billion for an RNAi obesity drug from Rona Therapeutics. Meanwhile, Merck and Moderna’s personalized melanoma vaccine cut the risk of recurrence or death by 42% in a Phase 3 trial. So,...

Strategic Intent: How Circio Rebuilt Itself Around Circular RNA 03.11.2026

Most biotech companies spend their time creating value. Far fewer have to figure out how to rebuild it. Erik Wiklund, CEO of Norwegian biotech Circio, has done both. Three and a half years ago, Circio ended its legacy oncolytic virus and cancer vaccine programs and pivoted to circular RNA, while it still had the resources to do so. The share price fell about 98%, the team shrank to eight people, a...

Strategic Intent: Understanding Crossover Strategies in Biotech With Sofinnova Partners’ David Evans 27.10.2026

In this episode of Strategic Intent, Partner at Sofinnova Partners, David Evans discusses his transition from Roche Venture Fund, different investments strategies, general market analysis across Europe and US, as well as growing therapeutics area trends within biotech.

Strategic Intent: Can Blood Tests Break the Alzheimer’s Diagnosis Bottleneck? 20.10.2026

Disease-modifying Alzheimer’s treatments have arrived, but diagnosing the right patients at scale is still a major bottleneck. In this episode of Strategic Intent, Marion Webb (MedTech Insight) speaks with Dr. Soeren Mattke, research professor of economics at USC, director of the Brain Health Observatory, and member of the scientific advisory board of ALZpath, about how FDA-cleared blood tests are...

Strategic Intent: Celebrity Marketing In The Age Of Promo Crackdown 13.10.2026

Can a celebrity campaign still work for a drug company when the FDA is watching every word? In this episode of Strategic Intent, Frank Watanabe, CEO of Arcutis Biotherapeutics, discusses the company’s latest brand awareness push and what it takes to commercialize a topical dermatology drug in an increasingly scrutinized promotional environment.​​ Commercial strategies, ad campaigns, dermatology

Strategic Intent: Using Agentic AI To Create ‘The Self-Driving Clinical Trial, Kind Of Like The Car’ 06.10.2026

In this Strategic Intent episode, In Vivo speaks with Ken Getz, executive director of the Tufts CSDD and research professor at the Tufts University School of Medicine, and Pamela Tanaerts, CMO and CSO at Medable, to discuss promising data from an AI Clinical Monitoring Agent.

Proof of Concept - Can AI Outrun the Next Outbreak? 02.10.2026

What if you could design a diagnostic and a therapeutic directly from a pathogen's genetic code, faster than the disease can spread? Jared Bauer, co-founder and CEO of Seek Labs, joins Proof of Concept to explain how his company's AI engine maps conserved targets across 145+ pathogens to build programmable CRISPR therapeutics and rapid, lab-free diagnostics.

Assessing the current dealmaking environment for psychedelic medicine. 01.10.2026

Joseph Haas and Emma Wille overview the dealmaking environment for psychedelic medicine given recent developments in the space: Eli Lilly's $2.8 billion acquisition of AtaiBeckley in July, the imminent FDA filing of Compass Pathways' COMP360 for treatment-resistant depression and a more relaxed regulatory environment for psychedelic therapies under the current administration.

Strategic Intent: Boehringer Ingelheim's Brian Hilberdink on Launching Into the GLP-1 Era 28.09.2026

Brian Hilberdink, President of US Human Pharma at Boehringer Ingelheim, joined Strategic Intent to talk about leading one of the company's most ambitious US launch periods in years, spanning a specialty drug in interstitial lung disease, an established franchise in cardiometabolic disease and a potential entry into the hyper-competitive obesity market. He discusses how private ownership shapes lon...

Strategic Intent: Rubedo’s Seno-Adaptive Bet On Longevity Medicine 21.09.2026

In this episode of Strategic Intent, In Vivo senior reporter David Wild speaks with Frederick Beddingfield, CEO of Rubedo Life Sciences, about turning the biology of aging into real medicines. They discuss Rubedo’s lead topical GPX4 modulator RLS‑1496 in actinic keratosis, psoriasis, atopic dermatitis, and photo‑aged skin; a new push into androgenetic alopecia; and the company’s “seno-adaptive” ap...

Strategic Intent: Next‑Generation Cancer Vaccines And Nouscom’s Strategy For Interception And Personalization 15.09.2026

Personalized and off‑the‑shelf cancer vaccines are moving from concept to clinic, raising new questions about differentiation, manufacturability, and commercial value. In this episode of Strategic Intent, In Vivo’s David Wild speaks with Marina Udier, CEO of Nouscom, about how the Basel‑based biotech is positioning its viral vector platform in this evolving landscape. They discuss NOUS‑209, an off...

Strategic Intent: Evolving Requirements Of Life Sciences Leadership 08.09.2026

In this episode of Strategic Intent, Nick Stephens, chairman of the recruitment and executive placement company RSA group, looks at the state of executive leadership across the life sciences and biotech industries, reflecting on inflection points for hiring practices and emerging structural trends.

Proof Of Concept: How A Charity Bridges Lab And Clinic 04.09.2026

Cancer Research UK is best known for funding science. But its commercial arm, Cancer Research Horizons, does something less obvious: it builds companies. This episode features Phil Masterson and Neil Jones, who run its ventures and drug discovery arms, unpacking why charities are increasingly bridging the gap between a promising result in the lab and a medicine in the clinic. Drug discovery, oncol...

Strategic Intent: Beyond The Breakthrough - From Approval To Adoption 01.09.2026

A medical device can work beautifully and still go nowhere. In this episode of Strategic Intent, Krishna Eluri sits down with Mark Saxton, U.S. CEO of Baird Medical, who has spent more than 25 years bringing first-of-their-kind procedural technologies to market. Their conversation digs into medtech's hardest problem — not inventing a technology, but getting physicians to switch and payers to cover...

ZS On How AI is Reshaping The Patient's Approach to Care Delivery - a View From the US, China and Germany 31.08.2026

A landmark three-country survey by the ZS consulting and technology firm , which shows the rapid trend towards patients' uptake of AI tools that empower them on their healthcare journeys. ZS’ Jon Roffman and Bhargav Mantha set the scene.

Videocast: Goodwin’s Sophie McGrath – A Legal View Of Healthtech And Biopharma Trends 25.08.2026

a videocast for the In Vivo podcast section, with Goodwin's Sophie McGrath - talking about healthtech and pharma trends. Innovation, investment, legal, Goodwin, Sophie McGrath, EU, Europe

Bonus Episode: Inside Endocyclic’s Precision Peptide Strategy For Endometriosis Diagnosis And Treatment 21.08.2026

One in ten women has endometriosis, yet treatment options remain largely unchanged for decades. Tanya Petrossian, CEO of EndoCyclic Therapeutics, explains how her company's non-hormonal peptide platform - now FDA-cleared for human trials - could finally change that.

In Vivo Trailer 19.08.2026
Strategic Intent: The Rise Of Mid-Cap Dealmakers 17.08.2026

Biopharma’s small-to-mid-cap players are stepping up as serious acquirers. David Wild and Scrip’s Jessica Merrill unpack how companies like argenx, Insmed, Jazz, Genmab, UCB, and BioMarin are using M&A to extend growth beyond their first commercial successes and what that shift means for investors, dealmaking, and the next generation of big biotechs.

Strategic Intent: First-in-class, two markets: Annexon’s GBS and GA Strategies 11.08.2026

On this episode of Strategic Intent, In Vivo’s David Wild sits down with Doug Love, President and CEO of Annexon Inc., to discuss how the company is transitioning from a platform-centric biotech into a commercial organization. Love walks through the distinct go-to-market strategies for an acute rare disease treated in hospitals versus a large chronic ophthalmology market served by retina practices...

Proof of Concept - AI in Drug Discovery 07.08.2026

In this episode of Proof of Concept, Krishna Bulusu joins us for an honest, industry-wide look at what AI and simulation can and can't do. Having spent years in oncology data science at AstraZeneca before becoming VP of Product Innovation & Strategy at Turbine, he's seen the problem from both sides — as the big-pharma adopter deciding whether to trust these tools, and as the builder creating them....

Listen to the In Vivo Podcasts podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.